Acetylation on critical lysine residues of Apurinic/apyrimidinic endonuclease 1 (APE1) in triple negative breast cancers(742 views) Poletto M, Di Loreto C, Marasco D, Poletto E, Puglisi F, Damante G, Tell G
Biochemical And Biophysical Research Communications (ISSN: 0006-291x), 2012 Jul 20; 424(1): 34-39.
Keywords: Acetylation, Apurinic Apyrimidinic Endonuclease Redox Effector Factor 1 (ape1 Ref-1), Base Excision Repair (ber), Triple Negative Breast Cancer (tnbc), Lysine Derivative, Polyclonal Antibody, Article, Cancer Prognosis, Cohort Analysis, Controlled Study, Female, Human, Human Cell, Immunofluorescence, Immunohistochemistry, Priority Journal, Protein Synthesis, Amino Acid Sequence, Breast Neoplasms, Dna-(apurinic Or Apyrimidinic Site) Lyase, Molecular Sequence Data, Protein Processing, Post-Translational, Tumor Cells, Cultured, Mammalia,
Affiliations: *** IBB - CNR ***
Department of Medical and Biological Sciences, University of Udine, 33100 Udine, Italy
Department of Biological Sciences, University of Naples Federico II, 80134 Naples, Italy
Institute of Biostructures and Bioimaging, National Research Council, 80134 Naples, Italy
References: Not available.
Acetylation on critical lysine residues of Apurinic/apyrimidinic endonuclease 1 (APE1) in triple negative breast cancers
Protein acetylation plays many roles within living cells, modulating metabolism, signaling and cell response to environmental stimuli, as well as having an impact on pathological conditions, such as cancer pathogenesis and progression. The Apurinic/apyrimidinic endonuclease APE1 is a vital protein that exerts many functions in mammalian cells, acting as a pivotal enzyme in the base excision repair (BER) pathway of DNA lesions, as transcriptional modulator and being also involved in RNA metabolism. As an eclectic and abundant protein, APE1 is extensively modulated through post-translational modifications, including acetylation. Many findings have linked APE1 to cancer development and onset of chemo- and radio-resistance. Here, we focus on APE1 acetylation pattern in triple negative breast cancer (TNBC). We describe the validation and characterization of a polyclonal antibody that is specific for the acetylation on lysine 35 of the protein. Finally, we use the new antibody to analyze the APE1 acetylation pattern on a cohort of TNBC specimens, exploiting immunohistochemistry. Our findings reveal a profound deregulation of APE1 acetylation status in TNBC, opening new perspectives for future improvements on treatment and prognosis of this molecular subtype of breast carcinomas. (C) 2012 Elsevier Inc. All rights reserved.
Acetylation on critical lysine residues of Apurinic/apyrimidinic endonuclease 1 (APE1) in triple negative breast cancers
No results.
Acetylation on critical lysine residues of Apurinic/apyrimidinic endonuclease 1 (APE1) in triple negative breast cancers
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(458 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote